Enjoy complimentary customisation on priority with our Enterprise License!
The anticoagulants market size is estimated to grow by USD 20.14 billion at a CAGR of 8.68% between 2023 and 2028. The market is experiencing significant growth due to the introduction of novel oral anticoagulants (NOACs) that offer several advantages over traditional vitamin K antagonists, such as reduced risk of bleeding and easier administration. Warfarin is employed for various indications, including DVT/PE, AF, and other coagulation disorders. Moreover, the surge in hip and knee surgeries, often requiring anticoagulation therapy post-operation, contributes significantly to market growth. Another trend in the market is the advent of anticoagulant antidotes, which provide effective reversal of anticoagulant effects in emergency situations. However, the market also faces challenges, including the strong side-effects of anticoagulants, such as bleeding complications, and the high cost of these medications, which may limit their accessibility to some patient populations. Overall, the market is expected to continue growing due to the increasing prevalence of cardiovascular diseases and the development of new anticoagulant therapies.
To learn more about this report, Request Free Sample
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories: The company offers anticoagulants such as ACITROM, which functions as a vitamin K antagonist.
The report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Abbott Laboratories, Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Novartis AG, Pfizer Inc., Sanofi SA, Shenzhen Hepalink Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and United Therapeutics Corp.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the oral anticoagulants segment will be significant during the forecast period. Anticoagulant drugs play a significant role in managing chronic disorders associated with blood clot formation, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), and cardiovascular diseases such as coronary heart disease and stroke. Traditional anticoagulants, like warfarin, have been in use for over five decades and belong to the vitamin K antagonist drug category.
Get a glance at the market contribution of various segments Download PDF Sample
The oral anticoagulants segment was valued at USD 21.13 billion in 2018. In recent years, novel oral anticoagulants (NOACs) have emerged as a new drug class, offering advantages over traditional anticoagulants. NOACs, including rivaroxaban, betrixaban, apixaban, edoxaban, and dabigatran, function by inhibiting specific coagulation factors. These drugs have gained popularity due to their ease of use, fewer dietary restrictions, and quicker onset and offset of action. Genetic testing and pharmacogenomics play a crucial role in optimizing anticoagulant therapy, ensuring effective treatment, and minimizing risks. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample
North America is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period.
The North American market, including oral and injectable forms, has witnessed substantial expansion due to the rising incidence of thromboembolic events, particularly Deep Vein Thrombosis (DVT) and pulmonary embolisms. The US, with its high prevalence of thrombosis, accounts for approximately 23% of the global market share. According to the CDC, over 900,000 new cases of DVT and pulmonary embolism are reported annually in the US. Factors such as heightened awareness of these conditions and the advanced healthcare infrastructure contribute to market growth. Oral anticoagulants like Coumadin and indandiones, and injectable anticoagulants such as Factor XA inhibitors and direct thrombin inhibitors, are used to prevent clots in the coagulation pathway.
Moreover, Heparin, another anticoagulant, is used to manage Von Willebrand disease and prevent thromboembolic events. They are available at hospital pharmacies, online pharmacies, and retail pharmacies. They are essential for managing orthotic conditions and preventing ischemic stroke caused by thrombin. Modern biotechnology companies like Twist Bioscience are contributing to the development of advanced anticoagulants. These innovations aim to improve patient outcomes and reduce the risk of complications. As such, many companies are developing reverse agents and plan to launch some of them during the forecast period.
The market encompasses a wide range of drugs used for preventing the coagulation of blood and reducing the risk of blood clot formation in individuals with chronic disorders such as Deep Vein Thrombosis (DVT), Atrial Fibrillation (AF), Myocardial Infarction (MI), and Pulmonary Embolism (PE), which are common cardiovascular diseases. Novel oral anticoagulants and injectable anticoagulants are the two primary drug categories in this market. The route of administration varies between these two categories, with oral anticoagulants being more convenient for patients, while injectable anticoagulants are typically used for more severe conditions. Genetic testing is increasingly being used to identify individuals at higher risk for blood clotting disorders, leading to increased product penetration in the geriatric population and those with a prevalence of obesity. The coagulation pathway is the primary target for anticoagulant drugs, which function by inhibiting specific proteins involved in blood clotting. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increase in hip and knee surgeries is notably driving the global market growth. Anticoagulants are essential medications used to prevent the coagulation of blood and the formation of harmful clots in individuals with chronic disorders such as deep vein thrombosis, cardiovascular diseases, and atrial fibrillation. Traditional anticoagulants, administered via the parenteral route, were not well-received by patients due to their non-friendly nature and poor adherence.
Moreover, in response, the market has seen the introduction of novel oral anticoagulants, including direct thrombin inhibitors like dabigatran and anti-Xa agents such as apixaban, edoxaban, and rivaroxaban. These drugs, classified as new-age oral anticoagulants, are preferred by medical practitioners and patients due to their convenience and effectiveness. Therefore, an increase in hip and knee surgeries is expected to boost the growth of the global market during the forecast period.
Increasing focus on emerging economies is the primary trend in the global market. The market for anticoagulant drugs, used primarily in the treatment of deep vein thrombosis and various cardiovascular diseases, has faced limited growth due to the adverse side effects associated with these blood thinners. Novel oral anticoagulants, such as Rivaroxaban, Betrixaban, Apixaban, Edoxaban, and Dabigatran, have emerged as a drug category in recent years.
However, the lack of antidotes for these medications has posed a significant challenge. They are essential in preventing blood clot formation in individuals with chronic disorders like atrial fibrillation, myocardial infarction (MI), pulmonary embolism, and venous thromboembolism. Genetic testing and pharmacogenomics are increasingly being used to personalize treatment and minimize side effects. Hence, increasing focus on emerging markets will drive the growth of the global market during the forecast period.
Strong side effects of anticoagulants are a major challenge to the growth of the global market. Anticoagulants, also known as blood thinners, are essential medications used to prevent blood clot formation in individuals with chronic disorders such as deep vein thrombosis and cardiovascular diseases. These drugs hinder the coagulation of blood, slowing down the blood clotting process. However, they carry a high risk of side effects, including excess bleeding. Novel oral segment, including Rivaroxaban, Betrixaban, Apixaban, Edoxaban, and Dabigatran, are the primary drug category used for anticoagulation and fucoidan, a naturally occurring complex sulfated polysaccharide, is well-known for its health benefits, such as antioxidant, anti-inflammatory, and immune-enhancing properties. .
Moreover, genetic testing and pharmacogenomics play a crucial role in determining the effectiveness and safety of anticoagulant therapy. Stroke, venous thrombosis, coronary heart disease, atrial fibrillation, myocardial infarction, and pulmonary embolism are common conditions treated with anticoagulants. Thus, the increasing awareness of the side effects of anticoagulants is expected to hamper the growth of the global market during the forecast period.
The market forecast report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting and growth strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market encompasses the production and distribution of anticoagulant drugs and therapies. These substances prevent the coagulation of blood, reducing the risk of thrombosis and embolism. These are essential in managing various cardiovascular and other health conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The market is driven by the increasing prevalence of cardiovascular diseases and the growing awareness of their risks. The market is segmented based on product type, application, and region.
Furthermore, the market landscape depends on Blood clotting time, Cardiovascular disorders, Obese and elderly people, Artery Direct oral anticoagulants (DOACs) and heparin are the primary product types, while applications include therapeutic and prophylactic uses. Key players in the market include Daiichi Sankyo, Bayer, and Novo Nordisk. They focus on research and development, strategic collaborations, and expanding their product portfolios to maintain their market position. Cardiovascular diseases remain a significant health concern worldwide, ensuring a steady demand. The market is expected to grow significantly due to the increasing prevalence of cardiovascular diseases and the rising awareness of their risks. The market's growth is further fueled by the development of new anticoagulant drugs and therapies. The market's future looks promising, with numerous opportunities for growth and innovation.
Market Scope |
|
Report Coverage |
Details |
Page number |
177 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.68% |
Market growth 2024-2028 |
USD 20.14 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.8 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 51% |
Key countries |
US, Germany, UK, Japan, and Canada |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Amphastar Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Novartis AG, Pfizer Inc., Sanofi SA, Shenzhen Hepalink Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and United Therapeutics Corp. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.